DTB is a DeepTech venture builder and co-founder.
Let's start a conversation
We partner with research groups and universities, support deep tech spinouts, collaborate with companies seeking validated innovation pipelines, and co-invest alongside institutional and private investors.
Schedule an appointmentWe identify technologies with the most potential
We minimize the risks and maximize the return in company creation
What we do
DTB translates high-potential science into market-ready companies. We source projects in AI, biotech, materials science, and engineering; select the most promising ones, and support them along the creation, growth, and industrialization field—driving the path from lab to first customers.
How we do it
Through a structured, milestone-driven playbook:
-
01
Eligibility & NDA — fit with our focus areas
-
02
Technology validation & technical de-risk
-
03
Initial business model design (applications, LOIs/PoCs)
-
04
Venture Building — company formation, branding, legal & corporate setup
-
05
Market Readiness — investor targeting, commercial & growth operations, and continued fundraising support
End-to-End Companies Creation
We co-create ventures from university research labs and public R&D centers, handling every step of the journey.
Technology scouting and evaluation
Team formation and talent matching
Business design and go-to-market strategy
Marketing and IP strategy
Capitalization and investor alignment
Legal structuring and governance
Growth, scaling, and exit planning
Evidence before scale, hands-on execution
Evidence before scale, hands-on execution (co-founders, not consultants), and aligned incentives through co-investment — so the best science reaches the market faster and with less risk.
Meet the team
Coming from diverse backgrounds, our combined experience builds the foundation of DeepTech Builder's success.
A founding team bringing over 50 years of combined leadership experience in R&D, technology transfer, deeptech investing, and startup operations — supported by a network of approximately 50 sector and clinical advisors.